Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study
Clinical Chemistry · 03.04.2024 · 70 (4) · 669-679
DOI: 10.1093/clinchem/hvae005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 22.02.2024. Verfasst von Huub H van Rossum und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Carcinoembryonic Antigen. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Roche, Health Holland. S. Holdenrieder, Abbott.
Abstract (Originalsprache)
Background
The harmonization status of most tumor markers (TMs) is unknown. We report a feasibility study performed to determine whether external quality assessment (EQA) programs can be used to obtain insights into the current harmonization status of the tumor markers α-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen (CA)125, CA15-3 and CA19-9.
Methods
EQA sample results provided by 6 EQA providers (INSTAND [Germany], Korean Association of External Quality Assessment Service [KEQAS, South Korea], National Center for Clinical Laboratories [NCCL, China], United Kingdom National External Quality Assessment Service [UK NEQAS, United Kingdom], Stichting Kwaliteitsbewaking Medische Laboratoriumdiagnostiek [SKML, the Netherlands], and the Royal College of Pathologists of Australasia Quality Assurance Programs [RCPAQAP, Australia]) between 2020 and 2021 were used. The consensus means, calculated from the measurement procedures present in all EQA programs (Abbott Alinity, Beckman Coulter DxI, Roche Cobas, and Siemens Atellica), was used as reference values. Per measurement procedure, the relative difference between consensus mean for each EQA sample and the mean of all patient-pool–based EQA samples were calculated and compared to minimum, desirable, and optimal allowable bias criteria based on biological variation.
Results
Between 19040 (CA15-3) and 25398 (PSA) individual results and 56 (PSA) to 76 (AFP) unique EQA samples were included in the final analysis. The mean differences with the consensus mean of patient-pool–based EQA samples for all measurement procedures were within the optimum bias criterion for AFP, the desirable bias for PSA, and the minimum bias criterion for CEA. However, CEA results <8 µg/L exceeded the minimum bias criterion. For CA125, CA15-3, and CA19-9, the harmonization status was outside the minimum bias criterion, with systematic differences identified.
Conclusions
This study provides relevant information about the current harmonization status of 6 tumor markers. A pilot harmonization investigation for CEA, CA125, CA15-3, and CA19-9 would be desirable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, the Netherlands.
- Institute of Laboratory Medicine, Munich Biomarker Research Center, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
- INSTAND e.V., Society for Promoting Quality Assurance in Medical Laboratories, Duesseldorf, Germany.
- Department of Clinical Chemistry, Leiden University Medical Center, Leiden, the Netherlands.
- RCPA Quality Assurance Programs, St Leonards, Sydney, Australia.
- Department of Laboratory Medicine, Konkuk University Medical Center, Seoul, South Korea.
ORCID-Profile: Huub H van Rossum, Qing H Meng
Förderung
- Roche
- Health Holland. S. Holdenrieder
- Abbott
- Nova Biomedical
Zitieren
APA
van Rossum, H. H., Holdenrieder, S., Ballieux, B. E. P. B., Badrick, T. C., Yun, Y. M., Zhang, C., Patel, D., Thelen, M., Song, J., Wojtalewicz, N., Unsworth, N., Vesper, H. W., Cui, W., Ramanathan, L. V., Sturgeon, C., & Meng, Q. H. (2024). Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study. Clinical Chemistry, 70(4), 669-679. https://doi.org/10.1093/clinchem/hvae005
Vancouver
van Rossum HH, Holdenrieder S, Ballieux BEPB, Badrick TC, Yun YM, Zhang C, et al. Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study. Clinical Chemistry. 2024;70(4):669-679. doi:10.1093/clinchem/hvae005
BibTeX
@article{vanRossum2024,
author = {van Rossum, Huub H and Holdenrieder, Stefan and Ballieux, Bart E P B and Badrick, Tony C and Yun, Yeo-Min and Zhang, Chuanbao and Patel, Dina and Thelen, Marc and Song, Junghan and Wojtalewicz, Nathalie and Unsworth, Nick and Vesper, Hubert W and Cui, Wei and Ramanathan, Lakshmi V and Sturgeon, Catharine and Meng, Qing H},
title = {Investigating the Current Harmonization Status of Tumor Markers Using Global External Quality Assessment Programs: A Feasibility Study},
journal = {Clinical Chemistry},
year = {2024},
volume = {70},
number = {4},
pages = {669--679},
doi = {10.1093/clinchem/hvae005}
}
EUVIMED